The safety of biologic therapies in RA-associated interstitial lung disease

Nature Reviews Rheumatology

Volumn 10, Issue 5, 2014, Pages 284-294

  Jani, Meghna ^a   Hirani, Nik ^b   Matteson, Eric L ^c   Dixon, William G ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR ANTIBODY; BIOLOGICAL FACTOR;

ADULT RESPIRATORY DISTRESS SYNDROME; ALGORITHM; BIOLOGICAL THERAPY; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EVIDENCE BASED MEDICINE; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION TEST; MEDICAL DECISION MAKING; MEDICAL RESEARCH; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CODING; PATIENT MONITORING; PATIENT SELECTION; PHENOTYPE; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOID ARTHRITIS ASSOCIATED INTERSTITIAL LUNG DISEASE; RISK ASSESSMENT; COMPLICATION; LUNG DISEASES, INTERSTITIAL;

ARTHRITIS, RHEUMATOID; BIOLOGICAL FACTORS; HUMANS; LUNG DISEASES, INTERSTITIAL;

EID: 84899901101     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2013.197     Document Type: Review

References (97)

1. Ostor, A. J. et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J. Rheumatol. 33, 622-628 (2006
2. Castelino, F. V. & Varga, J. Interstitial lung disease in connective tissue diseases: Evolving concepts of pathogenesis and management. Arthritis Res. Ther. 12, 213 (2010
3. Turesson, C., O'Fallon, W. M., Crowson, C. S., Gabriel, S. E. & Matteson, E. L. Extra-Articular disease manifestations in rheumatoid arthritis: Incidence trends and risk factors over 46 years. Ann. Rheum. Dis. 62, 722-727 (2003
4. Peno-Green, L., Lluberas, G., Kingsley, T. & Brantley, S. Lung injury linked to etanercept therapy. Chest 122, 1858-1860 (2002
5. Liote, H., Liote, F., Seroussi, B., Mayaud, C. & Cadranel, J. Rituximab-induced lung disease: A systematic literature review. Eur. Respir. J. 35, 681-687 (2010
6. O'Connor, M. B., Abdullah, M. F., O'Donovan, N. & Phelan, M. J. Rituximab-induced pulmonary disease. Rheumatol. Int. 32, 2955-2956 (2012
7. Wada, T. et al. A case of rheumatoid arthritis complicated with deteriorated interstitial pneumonia after the administration of abatacept [Japanese]. Nihon Rinsho Meneki Gakkai Kaishi. 35, 433-438 (2012
8. Ikegawa, K., Hanaoka, M., Ushiki, A., Yamamoto, H. & Kubo, K. A case of organizing pneumonia induced by tocilizumab. Intern. Med. 50, 2191-2193 (2011
9. Kawashiri, S. Y., Kawakami, A., Sakamoto, N., Ishimatsu, Y. & Eguchi, K. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol. Int. 32, 4023-4026 (2012
10. Wendling, D. et al. Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis. Joint Bone Spine http://dx.doi.org/10.1016/j.jbspin.2013.03.009
11. Thrall, R. S., Vogel, S. N., Evans, R. & Shultz, L. D. Role of tumor necrosis factor-? in the spontaneous development of pulmonary fibrosis in viable motheaten mutant mice. Am. J. Pathol. 151, 1303-1310 (1997
12. Ortiz, L. A. et al. Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp. Lung. Res. 24, 721-743 (1998
13. Piguet, P. F., Ribaux, C., Karpuz, V., Grau, G. E. & Kapanci, Y. Expression and localization of tumor necrosis factor- ? and its mRNA in idiopathic pulmonary fibrosis. Am. J. Pathol. 143, 651-655 (1993
14. Kapanci, Y., Desmouliere, A., Pache, J. C., Redard, M. & Gabbiani, G. Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor ? and tumor necrosis factor ?. Am. J. Respir. Crit. Care Med. 152, 2163-2169 (1995
15. Raghu, G. et al. Treatment of idiopathic pulmonary fibrosis with etanercept: An exploratory, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 178, 948-955 (2008
16. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01266317 (2013
17. Winthrop, K. L. Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention. Rheum. Dis. Clin. North Am. 38, 727-745 (2012
18. Lipsky, P. E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343, 1594-1602 (2000
19. Klareskog, L. et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 363, 675-681 (2004
20. Weinblatt, M. E. et al. Adalimumab, a fully human anti-tumor necrosis factor ? monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum. 48, 35-45 (2003
21. Maini, R. N. et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 50, 1051-1065 (2004
22. van Vollenhoven, R. F. et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1 year results of a randomised trial. Lancet 374, 459-466 (2009
23. van Der Heijde, D. et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54, 1063-1074 (2006
24. Breedveld, F. C. et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54, 26-37 (2006
25. Burmester, G. R. et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: The Research in Active Rheumatoid Arthritis (ReAct) trial. Ann. Rheum. Dis. 66, 732-739 (2007
26. Ostor, A. J., Crisp, A. J., Somerville, M. F. & Scott, D. G. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ 329, 1266 (2004
27. Antoniou, K. M. et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin. Exp. Rheumatol. 25, 23-28 (2007
28. Vassallo, R., Matteson, E. & Thomas, C. F., Jr. Clinical response of rheumatoid arthritis-Associated pulmonary fibrosis to tumor necrosis factor-? inhibition. Chest 122, 1093-1096 (2002
29. Bargagli, E., Galeazzi, M. & Rottoli, P. Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis. Eur. Respir. J. 24, 708 (2004
30. Perez-Alvarez, R. et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: Analysis of 122 cases. Semin. Arthritis Rheum. 41, 256-264 (2011
31. Dascalu, C., Mrejen-Shakin, K. & Bandagi, S. Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis. J. Clin. Rheumatol. 16, 172-174 (2010
32. Yamazaki, H., Isogai, S., Sakurai, T. & Nagasaka, K. A case of adalimumab-Associated interstitial pneumonia with rheumatoid arthritis. Mod. Rheumatol. 20, 518-521 (2010
33. Cho, S. K., Oh, I. H., Park, C. K., Bae, S. C. & Sung, Y. K. Etanercept induced organizing pneumonia in a patient with rheumatoid arthritis. Rheumatol. Int. 32, 1055-1057 (2012
34. Horai, Y. et al. Eternacept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease. J. Clin. Pharm. Ther. 37, 117-121 (2012
35. Sakaida, H., Komase, Y. & Takemura, T. Organizing pneumonia in a patient with rheumatoid arthritis treated with etanercept. Mod. Rheumatol. 20, 611-616 (2010
36. Yokoyama, T. et al. A case of etanercept-induced pneumonitis [Japanese]. Nihon Kokyuki Gakkai Zasshi 47, 870-874 (2009
37. Hadjinicolaou, A. V. et al. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases-A systematic literature review. Rheumatology (Oxford) 50, 2297-2305 (2011
38. Pearce, F., Johnson, S. R. & Courtney, P. Interstitial lung disease following certolizumab pegol. Rheumatology (Oxford) 51, 578-580 (2012
39. Millar, A., McKew, J. & Taggart, A. Fatal fibrosing alveolitis with certolizumab. Rheumatology (Oxford) 51, 953-955 (2012
40. Glaspole, I. N., Hoy, R. F. & Ryan, P. F. A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis. Rheumatology (Oxford) 52, 2302-2304 (2013
41. Lager, J., Hilberg, O., Lokke, A. & Bendstrup, E. Severe interstitial lung disease following treatment with certolizumab pegol: A case report. Eur. Respir. Rev. 22, 414-416 (2013
42. Wolfe, F., Caplan, L. & Michaud, K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand. J. Rheumatol. 36, 172-178 (2007
43. Herrinton, L. J. et al. Association between anti TNF ? therapy and interstitial lung disease. Pharmacoepidemiol. Drug Saf. 22, 394-402 (2013
44. Dixon, W. G., Hyrich, K. L., Watson, K. D., Lunt, M. & Symmons, D. P. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-Associated interstitial lung disease: Results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 69, 1086-1091 (2010
45. Kim, Y. J. et al. Mortality in patients with rheumatoid arthritis-Associated interstitial lung disease treated with an anti-tumour necrosis factor agent [abstract 0210]. Ann. Rheum. Dis. 72 (Suppl. 3), 444 (2013
46. US Food and Drug Administration. Therapeutic Biological Products Approvals [online], http://www.fda.gov/drugs/developmentapprovalprocess/ howdrugsaredevelopedandapproved/approvalapplications/ therapeuticbiologicapplications/ucm080402.htm (2003
47. US Food and Drug Administration. Rituximab for moderate to severe rheumatoid arthritis [online], http://www.accessdata.fda.gov/drugsatfda-docs/ appletter/2006/103705s5211-ltr.pdf (2006
48. European Medicines Agency. Mabthera: Procedural steps taken and scientific information after authorisation [online], http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Procedural-steps-taken-and-scientific- information-after-authorisation/human/000165/WC500025820.pdf (2013
49. Haraoui, B., Bokarewa, M., Kallmeyer, I. & Bykerk, V. P. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: The RESET Trial. J. Rheumatol. 38, 2548-2556 (2011
50. Emery, P. et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54, 1390-1400 (2006
51. Emery, P. et al. Efficacy and safety of different doses and retreatment of rituximab: A randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX Inadequate Responders (SERENE)). Ann. Rheum. Dis. 69, 1629-1935 (2010
52. Mease, P. J. et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: Results from the SUNRISE trial. J. Rheumatol. 37, 917-927 (2010
53. Edwards, J. C. et al. Efficacy of B cell targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572-2581 (2004
54. Hadjinicolaou, A. V., Nisar, M. K., Parfrey, H., Chilvers, E. R. & Ostor, A. J. Non-infectious pulmonary toxicity of rituximab: A systematic review. Rheumatology (Oxford) 51, 653-662 (2012
55. Keir, G. J. et al. Severe interstitial lung disease in connective tissue disease: Rituximab as rescue therapy. Eur. Respir. J. 40, 641-648 (2012
56. Matteson, E. L. et al. Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-Associated interstitial pneumonia. Open J. Rheumatol. Autoimmune Dis. 2, 53-58 (2012
57. Becerra, E. & Leandro, M. J. Safety and efficacy of rituximab in patients with rheumatoid arthritis and lung involvement [abstract 502]. Arthritis Rheum. 64 (Suppl. S10), S220 (2012
58. Dass, S. et al. Safety of rituximab in patients with rheumatoid arthritis and concomitant lung disease [abstract 205]. Rheumatology (Oxford) 50 (Suppl. 3), iii121 (2011
59. Weinblatt, M. E. et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: Integrated analyses of up to 8 years of treatment from the Abatacept Clinical Trial Program. J. Rheumatol. 40, 787-797 (2013
60. US Food and Drug Administration. Abatacept for moderate to severe rheumatoid arthritis [online], http://www.accessdata.fda.gov/drugsatfda-docs/ appletter/2005/125118rev2.pdf (2005
61. Nishimoto, N. et al. Treatment of rheumatoid arthritis with humanized anti interleukin 6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50, 1761-1769 (2004
62. Smolen, J. S. et al. Effect of interleukin 6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 371, 987-997 (2008
63. Nishimoto, N. et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): Significant reduction in disease activity and serum vascular endothelial growth factor by IL 6 receptor inhibition therapy. Mod. Rheumatol. 19, 12-19 (2009
64. Gabay, C. et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial. Lancet 318, 1541-1550 (2013
65. US Food and Drug Administration. Tocilizumab for moderate to severe rheumatoid arthritis [online], http://www.accessdata.fda.gov/drugsatfda-docs/ appletter/2010/125276s000ltr.pdf (2009
66. European Medicines Agency. RoActemra, tocilizumab: Authorisation details 16/01/2009 [online], http://www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/000955/human-med-001042.jsp&mid= WC0b01ac058001d124 (2009
67. Yamanaka, H. et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: Results from a retrospective study (REACTION study). Mod. Rheumatol. 21, 122-133 (2011
68. Mohr, M. & Jacobi, A. M. Interstitial lung disease in rheumatoid arthritis: Response to IL 6R blockade. Scand. J. Rheumatol. 40, 400-401 (2011
69. Koike, T. et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: Interim analysis of 3881 patients. Ann. Rheum. Dis. 70, 2148-2151 (2011
70. Smolen, J. S., van Der Heijde, D., Machold, K. P., Aletaha, D. & Landewe, R. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2013-204317.
71. US Food and Drug Administration. Xeljanz (Tofacinitib) approval for moderate to severe rheumatoid arthritis [online], http://www.accessdata.fda.gov/ drugsatfda-docs/appletter/2012/203214Orig1s000ltr.pdf (2012
72. van Vollenhoven, R. F. et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367, 508-519 (2012
73. Fleischmann, R. et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 367, 495-507 (2012
74. Stenton, C. The MRC breathlessness scale. Occup. Med. (Lond.) 58, 226-227 (2008
75. Danoff, S. K., Terry, P. B. & Horton, M. R. A clinician's guide to the diagnosis and treatment of interstitial lung diseases. South. Med. J. 100, 579-587 (2007
76. Egan, J. J., Martinez, F. J., Wells, A. U. & Williams, T. Lung function estimates in idiopathic pulmonary fibrosis: The potential for a simple classification. Thorax 60, 270-273 (2005
77. Ley, B. et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann. Intern. Med. 156, 684-691 (2012
78. Latsi, P. I. et al. Fibrotic idiopathic interstitial pneumonia: The prognostic value of longitudinal functional trends. Am. J. Respir. Crit. Care Med. 168, 531-537 (2003
79. Raghu, G. et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183, 788-824 (2011
80. Hamblin, M. J. & Horton, M. R. Rheumatoid arthritis-Associated interstitial lung disease: Diagnostic dilemma. Pulm. Med. 2011, 872120 (2011
81. Flaherty, K. R. et al. Radiological versus histological diagnosis in UIP and NSIP: Survival implications. Thorax 58, 143-148 (2003
82. Kim, E. J. et al. Usual interstitial pneumonia in rheumatoid arthritis-Associated interstitial lung disease. Eur. Respir. J. 35, 1322-1328 (2010
83. Wells, A. U. & Hogaboam, C. M. Update in diffuse parenchymal lung disease 2007. Am. J. Respir. Crit. Care Med. 177, 580-584 (2008
84. Goh, N. S. et al. Interstitial lung disease in systemic sclerosis: A simple staging system. Am. J. Respir. Crit. Care Med. 177, 1248-1254 (2008
85. Sathi, N., Urwin, T., Desmond, S. & Dawson, J. K. Patients with limited rheumatoid arthritis-related interstitial lung disease have a better prognosis than those with extensive disease. Rheumatology (Oxford) 50, 620 (2011
86. Mann, D. L. et al. Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109, 1594-1602 (2004
87. Kwon, H. J., Cote, T. R., Cuffe, M. S., Kramer, J. M. & Braun, M. M. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med. 138, 807-811 (2003
88. Saketkoo, L. A. et al. Developing an index for disease activity and therapeutic response in connective tissue disease related interstitial lung disease: Results from a Delphi exercise: Delivering a consensus on domains. Arthritis Rheum. 64, 1713 (2012
89. Cottin, V., Capron, F., Grenier, P. & Cordier, J. F. Diffuse idiopathic interstitial pneumonias. International multidisciplinary consensus classification by the American Thoracic Society and the European Respiratory Society, principal clinico-pathological entities, and diagnosis [French]. Rev. Mal. Respir. 21, 299-318 (2004
90. Collard, H. R. et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 168, 538-542 (2003
91. Bottomley, A., Jones, D. & Claassens, L. Patient-reported outcomes: Assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency. Eur. J. Cancer. 45, 347-353 (2009
92. Speight, J. & Barendse, S. M. FDA guidance on patient reported outcomes. BMJ 340, c2921 (2010
93. Pope, J. Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler's Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud's Condition Score (RCS). Arthritis Care Res. (Hoboken) 63, S98-S111 (2011
94. Minnock, P., Kirwan, J. & Bresnihan, B. Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis. Rheumatology (Oxford) 48, 1533-1536 (2009
95. Boers, M., Brooks, P., Strand, C. V. & Tugwell, P. The OMERACT filter for outcome measures in rheumatology. J. Rheumatol. 25, 198-199 (1998
96. Makol, A., Wright, K. & Matteson, E. L. Safe use of antirheumatic agents in patients with comorbidities. Rheum. Dis. Clin. North Am. 38, 771-793 (2012
97. Zink, A. et al. European biologicals registers: Methodology, selected results and perspectives. Ann. Rheum. Dis. 68, 1240-1246 (2009